A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...

Compared with adults aged 65 and older, those aged 18 to 64 are more affected by long COVID neurologic symptoms.

Dysgeusia is an uncommonly reported side effect associated with angiotensin-converting enzyme inhibitors (ACE inhibitors). [1] The onset is almost always within the first 3 months and is ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

Other adverse reactions (incidence <5%) that occurred more frequently with Rezdiffra compared with placebo were decreased appetite, flatulence, abnormal feces, dysgeusia, vertigo, arrhythmia ...

Vaccination prior to COVID-19 infection does not significantly affect neurological symptoms in patients with postacute sequelae of SARS-CoV-2 infection.

Ever wake up with that weird metallic taste in your mouth? It's more common than you think, but don't worry, there's a fix!